Former Lacoste, Under Armor, Nautica Executive to Co-Lead Company’s Textile Sales; Brings 20+ Years of Global Textile Supply Chain Operations, Stewardship and Industry Thought Leadership to Applied DNA
STONY BROOK N.Y., October 4, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, today announced that it has appointed Wayne Buchen as Vice President of Strategic Sales, effective immediately, to lead the Company’s global textile Strategic Sales efforts. With over 20 years of sales, sourcing and operations experience with established international brands, Mr. Buchen will drive the development and execution of sales strategies to expand Applied DNA’s presence across global textile markets.
Mr. Buchen most recently served as Senior Vice President of Global Sourcing and Operations for Lacoste in Hong Kong and Senior Vice President of Global Sourcing in New York. He previously held leadership positions at Under Armor, Li & Fung, VF Corporation, Nautica and Liz Claiborne.
“Wayne’s deep experience with the needs of today’s brands makes him a great and timely fit for Applied DNA as we move to expand our penetration of the global textile market,” said Dr. James A. Hayward, president and CEO of Applied DNA. “His many years of supply chain operations and sourcing for leading apparel brands give him a unique perspective on how to position our CertainT platform for maximum effect for adoption by brands and textile manufacturers worldwide, as business imperatives centered on sustainability and the circular economy continue to be embraced by textile ecosystem participants.”
Mr. Buchen, together with MeiLin Wan, vice president of Textile Sales, will lead the Company’s sales efforts in its textile vertical. Mr. Buchen will be responsible for the strategic sales direction, focusing on business development, key accounts, integrated value chain propositions and new customer relationships and partner development. He will also design and implement go-to-market strategies for new applications of Applied DNA’s CertainT platform in textiles.
Mr. Steve Birkhold, CEO of UL Brands and a veteran of brand creation said: “Wayne has consistently worked on innovative solutions to problem solve many issues throughout his career. This initiative has the opportunity to transform the fashion/textile industry. Wayne’s partnership will add tremendous value to the company.”
“Applied DNA is at a pivotal point where potential partners recognize that our molecular business solutions are critical components of the value chain. The applications for our advanced technology are diverse and I am energized to have Wayne enhancing and expanding our partnerships across the textiles industry,” said Ms. Wan.
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.
We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.
Applied DNA also leverages its DNA knowledge to the benefit of the biotherapeutics market through, a wholly owned subsidiary that seeks to commercialize the biotherapeutic value of the Company’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction.
The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, firstname.lastname@example.org
Media contact: Angie Mathews, 781-639-4924, email@example.com
Program contact: MeiLin Wan, 631-240-8849, firstname.lastname@example.org